Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,069 public trials 582 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Active, Not Recruiting

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

NCT05028348

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • CHRU Hôtel Dieu Nantes, France
  • CHU Hôpital Saint Antoine Paris, France
  • La Pitié Paris, France
  • Klinikum Chemnitz Chemnitz, Germany
View all 20 locations
View Trial Details
Active, Not Recruiting

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

NCT01838512

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Local Institution Birmingham, Alabama, United States
  • Local Institute Goodyear, Arizona, United States
  • Local Institution - 0023 Anaheim, California, United States
  • Local Institution Anaheim, California, United States
View all 130 locations
View Trial Details
Active, Not Recruiting

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

NCT04174196

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Commack Commack, New York, United States
View Trial Details
Active, Not Recruiting

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

NCT04091126

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Westwood, Kansas, United States
  • GSK Investigational Site Charlotte, North Carolina, United States
  • GSK Investigational Site Madison, Wisconsin, United States
  • GSK Investigational Site Newcastle, New South Wales, Australia
View all 30 locations
View Trial Details
Active, Not Recruiting

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

NCT02253316

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Emory University - Winship Cancer Institute Atlanta, Georgia, United States
View Trial Details

Related conditions